Register  /  Login               

Mid-year review: the top 10 deals of 2018

corresponding

Patricia Van Arnum
DCAT Editorial Director

Abstract

As we come to the mid-point of 2018, which mergers and acquisitions among pharmaceutical companies have been noteworthy? Two $60-billion-plus deals top the list:
Bayer’s $63-billion acquisition of Monsanto, an agrochemical and seed company, which solidifies Bayer’s move to become a pure-play life sciences company and akeda’s pending $62-billion acquisition of Shire.


SO WHICH MERGERS AND ACQUISITIONS AMONG PHARMACEUTICAL COMPANIES HAVE MADE THE MARK THUS FAR IN 2018? DCAT VALUE CHAIN INSIGHTS TAKES AN INSIDE LOOK

Two $60-billlion deals top the list. First is Bayer’s $63-billion acquisition of Monsanto, an agrochemical and seed company, the largest deal in Bayer’s history and a move to fortify its strategy of being a pure-play life-sciences company. The second is Takeda’s proposed $62-billion acquisition of Shire, coming just two years after Shire’s $32-billion acquisition of Baxalta, the biopharmaceutical company spun off from Baxter Healthcare. What other deals of import have been made thus far in 2018? 

 

2018’s leading deals thus far 

  1. Bayer’s $63-billion acquisition of Monsanto. Bayer completed its $63-billion acquisition of Monsanto, an agrochemical and seed company in June 2018. The deal was the largest in Bayer’s history and ended a two-year effort to acquire the company. The move fortified Bayer’s strategy of being ...
  2. ...



About us



Teknoscienze publisher
& Event Organizer

Viale Brianza, 22
20127 - Milano - Italy

info@teknoscienze.com
Tel. +39 02 26809375